Union Minister of State for Science and Technology, Jitendra Singh, stated that India is steadily evolving into a robust ...

Ligand Pharma (LGND) outperforms via a high-margin royalty model and disciplined investing. Click here to read my most recent ...

Both have plenty to offer investors, but one has a better outlook.

MANILA, Philippines — The country’s pharmaceutical market is expected to reach P759 billion by 2030, supported by investments in local drug manufacturing, according to research and analysis firm BMI.

Catalyst Pharmaceuticals (NASDAQ:CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a ...

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug ...

Rapid Micro Biosystems, Inc. sees strong FY25 revenue growth from Growth Direct placements, but losses persist. Click for ...

The primary growth drivers in Bayer’s pharma sector—Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. But that won’t lead ...

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

BioMarin Pharmaceutical (NASDAQ:BMRN) executives highlighted 2025 revenue growth, improving profitability leverage, and a slate of clinical and commercial catalysts expected in 2026 during a ...